The threat of action from lawmakers may have put a damper on pharma's tax inversion frenzy, but it has not stopped the wave of deals that are taking American drugmakers overseas. Next up could be Illinois' Akorn, which is reportedly looking into a...
This week’s patent expirations are related to UCB’s (OTCPK:UCBJF) Vimpat, a seizure medication, and Genentech’s [now owned by Roche (OTCQX:RHHBY)] Nutropin Depot.
Vimpat launched in 2009 as an...
Shedding noncore assets is the trend du jour in Big Pharma, and now another company may be jumping on the bandwagon. Belgium's UCB is reportedly looking into a sale of Kremers Urban Pharmaceuticals, its Princeton, NJ-based generics unit.
UCB S.A. (OTCPK:UCBJF)
Q2 2014 Results Earnings Conference Call
July 30, 2014, 08:00 AM ET
Roch Doliveux - CEO
Jean-Christophe Tellier - CEO-Elect
Detlef Thielgen - EVP and CFO
Richard Park - Deutsche...
A new epilepsy treatment from Belgian drugmaker UCB helped reduce the rate of seizures in a Phase III trial, the company said, setting the stage for an FDA application and a shot at widening its footprint in the field.
Infotrieve, Inc. (www.infotrieve.com),
the leader in global-enterprise SaaS software and business services for
scientific, technical and medical (“STM”) published content access and
management, today announced that it has...
PARIS (MedPage Today) -- The benefits of treatment with certolizumab pegol (Cimzia) among patients with axial spondyloarthritis have persisted for 2 years, both for those with and without radiographic evidence of sacroiliitis, researchers reported...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to UCB SA (UCB-BT):